PL2419114T3 - Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej - Google Patents

Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej

Info

Publication number
PL2419114T3
PL2419114T3 PL10769192.5T PL10769192T PL2419114T3 PL 2419114 T3 PL2419114 T3 PL 2419114T3 PL 10769192 T PL10769192 T PL 10769192T PL 2419114 T3 PL2419114 T3 PL 2419114T3
Authority
PL
Poland
Prior art keywords
prophylaxis
treatment
degenerative disease
bacterial compositions
bacterial
Prior art date
Application number
PL10769192.5T
Other languages
English (en)
Other versions
PL2419114T5 (pl
Inventor
Satya Prakash
Mitchell Lawrence Jones
Christopher Martoni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43031618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2419114(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2419114T3 publication Critical patent/PL2419114T3/pl
Publication of PL2419114T5 publication Critical patent/PL2419114T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C2220/00—Biochemical treatment
    • A23C2220/20—Treatment with microorganisms
    • A23C2220/204—Use of bacteria which are encapsulated, entrapped or immobilised; Fermentation with these bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
PL10769192T 2009-05-01 2010-04-30 Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej PL2419114T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17474009P 2009-05-01 2009-05-01
EP10769192.5A EP2419114B2 (en) 2009-05-01 2010-04-30 Bacterial compositions for prophylaxis and treatment of degenerative disease
PCT/CA2010/000660 WO2010124387A1 (en) 2009-05-01 2010-04-30 Bacterial compositions for prophylaxis and treatment of degenerative disease

Publications (2)

Publication Number Publication Date
PL2419114T3 true PL2419114T3 (pl) 2016-09-30
PL2419114T5 PL2419114T5 (pl) 2019-09-30

Family

ID=43031618

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10769192T PL2419114T5 (pl) 2009-05-01 2010-04-30 Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej

Country Status (14)

Country Link
US (1) US10660857B2 (pl)
EP (2) EP3067056A1 (pl)
JP (2) JP6100526B2 (pl)
KR (1) KR20120015335A (pl)
CN (1) CN102481322A (pl)
AU (1) AU2010242498A1 (pl)
BR (1) BRPI1009920A2 (pl)
CA (1) CA2796929C (pl)
DK (1) DK2419114T4 (pl)
ES (1) ES2578081T5 (pl)
HR (1) HRP20160598T4 (pl)
PL (1) PL2419114T5 (pl)
RU (1) RU2571211C2 (pl)
WO (1) WO2010124387A1 (pl)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571211C2 (ru) 2009-05-01 2015-12-20 ЮАС ЛЭБОРЭТОРИЗ ЭлЭлСи Бактериальные композиции для профилактики и лечения дегенеративного заболевания
AU2011257964B2 (en) 2010-05-24 2014-10-30 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
EP2581092B2 (en) 2010-06-08 2020-03-11 Asahi Group Holdings, Ltd. Agent for improving lipid metabolism
TWI355939B (en) * 2011-01-14 2012-01-11 Genmont Biotech Inc Composition and use of probiotic strain gm-263 (ad
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
WO2013027087A1 (en) * 2011-08-23 2013-02-28 Compagnie Gervais Danone A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection
JP2014525266A (ja) * 2011-08-26 2014-09-29 マイクロバイオータ ダイアグノスティクス， エルエルシー 心欠陥を診断および治療する方法
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
US9737559B2 (en) 2011-11-23 2017-08-22 Ozstar Therapeutics Pty Ltd Synergistic anti-diabetic compositions
WO2013081462A1 (en) * 2011-12-02 2013-06-06 Universiteit Maastricht Phytostanols for the prevention or treatment of hepatic inflammation
JP5571650B2 (ja) * 2011-12-27 2014-08-13 農業生産法人株式会社 熱帯資源植物研究所 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
JP5525511B2 (ja) * 2011-12-27 2014-06-18 農業生産法人株式会社 熱帯資源植物研究所 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
PL2800563T3 (pl) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc. Wzbogacone w DPA kompozycje wielonienasyconych kwasów tłuszczowych omega-3 w postaci wolnego kwasu
CN102690856A (zh) * 2012-05-30 2012-09-26 绵阳劲柏生物科技有限责任公司 微生物溶液制作游离型胆汁酸的工艺
EP3401396A1 (en) * 2012-10-03 2018-11-14 Metabogen AB Treating or preventing atherosclerosis or associated diseases by beta-carotene
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2956006A4 (en) 2013-02-04 2017-02-22 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
CN105431173B (zh) * 2013-06-11 2020-12-22 好侍健康食品株式会社 向吞噬细胞运输物质的载体
JP2016521744A (ja) * 2013-06-13 2016-07-25 ファスト フォワード ファーマスーティカルズ ベー．フェー． 追加化合物が胆汁酸、胆汁酸誘導体、ｔｇｒ５受容体作動物質、ｆｘｒ作動物質またはそれらの組合せである、慢性炎症の治療および消化器癌または線維症の予防のためのｃｄ４０シグナル伝達阻害物質および追加化合物
SG10201710601YA (en) * 2013-07-02 2018-02-27 Austrianova Singapore Pte Ltd A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containing freeze-dried encapsulated cells and uses of such cells and compositions
GB201319538D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319540D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
JP2018500048A (ja) 2013-11-05 2018-01-11 オプティバイオティックス リミティド プレバイオティック組成物及びその製造方法
GB201319539D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319531D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
AU2014352643A1 (en) 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
GB2524474B (en) * 2014-03-07 2018-01-31 Genmont Biotech Inc Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes
JP2017528499A (ja) * 2014-09-25 2017-09-28 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CN105132327B (zh) 2015-09-09 2018-12-11 华南理工大学 一种多环芳烃污染修复微囊材料及其制备方法和应用
CN108697138A (zh) * 2015-12-17 2018-10-23 Cj第制糖株式会社 肠道存活率提高的乳酸菌的涂布方法
FR3045383B1 (fr) * 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
CN106361739A (zh) * 2016-08-29 2017-02-01 大连槿藏商贸有限公司 共轭亚油酸或其衍生物在制备乙醛脱氢酶促进剂方面的应用
US11447738B2 (en) 2016-10-28 2022-09-20 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
KR20180049731A (ko) 2016-11-03 2018-05-11 주식회사 쎌바이오텍 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
KR101938865B1 (ko) * 2016-11-03 2019-01-16 주식회사 쎌바이오텍 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
US10590496B2 (en) 2016-11-29 2020-03-17 Wedea Inc. Composition for preventing and treating degenerative brain disease using novel lactic acid bacteria
WO2018151186A1 (ja) * 2017-02-16 2018-08-23 味の素株式会社 ポリマービーズ
KR101999693B1 (ko) * 2017-06-13 2019-07-15 부산대학교 산학협력단 산성 환경에서 프로바이오틱스를 보호하는 프로바이오틱스 전달용 하이드로겔 제제 및 이를 포함하는 프로바이오틱스 전달용 조성물
CN107365705B (zh) * 2017-07-14 2021-01-12 江苏微康生物科技有限公司 一种油溶性益生菌冻干菌粉的冻干保护剂及其应用
CA3072206A1 (en) 2017-08-14 2019-02-21 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CN111465684B (zh) * 2017-09-29 2023-03-31 庆熙大学校产学协力团 新型乳酸菌及其应用
CA3079695A1 (en) * 2017-11-08 2019-05-16 Pasquale DEL GAUDIO In situ gelifying powder
CN108102985B (zh) * 2018-02-12 2020-08-04 江南大学 一种复配天然酵母发酵制备面包的方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN108841898A (zh) * 2018-07-16 2018-11-20 安徽民祯生物工程有限公司 一种透性化酵母细胞生产海藻糖的方法
AU2019308183A1 (en) * 2018-07-16 2021-01-28 The Medical College Of Wisconsin, Inc. Reutericyclin or Lactobacillus reuterii for reducing weight gain
WO2020068936A1 (en) * 2018-09-25 2020-04-02 Duke University Methods and compositions to treat and prevent infection
CN109266766B (zh) * 2018-10-10 2021-10-19 中国人民解放军第三0二医院 肠道微生物作为胆管细胞癌诊断标志物的用途
KR102447791B1 (ko) * 2018-10-30 2022-10-04 씨제이웰케어 주식회사 유산균의 동결 보호를 위한 시스테인 또는 이의 염의 용도
AU2019394973A1 (en) * 2018-12-07 2021-06-03 Pivot Bio, Inc. Polymer compositions with improved stability for nitrogen fixing microbial products
CN110108815B (zh) * 2019-05-24 2022-01-04 江西省科学院生物资源研究所 一种用于二十八烷醇预防肝损伤效果的体外评价方法
CN112007051B (zh) * 2019-05-28 2022-05-10 景岳生物科技股份有限公司 一种预防中风及改善中风严重度的组合物及其用途
US20220331377A1 (en) 2019-09-09 2022-10-20 River Stone Biotech Isg Aps Delivery vehicle for in situ delivering of pharmaceutical agents
TWI719691B (zh) * 2019-10-28 2021-02-21 葡萄王生技股份有限公司 羅伊氏乳桿菌（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｅｕｔｅｒｉ）菌株ＧＫＲ１用於製備降低尿酸之組成物的用途
KR102274678B1 (ko) * 2020-07-16 2021-07-12 (주)코엔바이오 신규한 락토바실러스 플란타룸 아종 플란타룸 Ｃｅｂ－ｋｃ－００７ 균주 및 이를 포함하는 항비만 효능을 가지는 조성물
CN112168847A (zh) * 2020-09-30 2021-01-05 浙江大学 罗伊氏乳杆菌在制备治疗急性肝衰竭药物中的用途
CN112618665B (zh) * 2020-12-19 2022-06-14 杭州益品新五丰药业有限公司 一种提高免疫反应的糠甾醇-谷维素联合用药制剂
CN112603912A (zh) * 2020-12-23 2021-04-06 广东省农业科学院动物科学研究所 罗伊氏菌素在畜禽养殖方面的应用
KR102215599B1 (ko) * 2020-12-28 2021-02-15 주식회사 에이치이엠 신규한 비피도박테리움 애니멀리스 락티스 hem20-01 균주, 및 상기 균주 또는 이의 배양물을 포함하는 우울증 치료용 조성물
CN113604402B (zh) * 2021-08-30 2023-07-21 江苏恒顺醋业股份有限公司 一种特异性的乳酸菌培养基及其培养方法和应用
EP4166002A1 (en) * 2021-10-12 2023-04-19 Evonik Operations GmbH Microbial preparations containing specific cryoprotectants
CN114107066A (zh) * 2021-11-19 2022-03-01 广东容大生物股份有限公司 高活性高稳定性益生菌规模化制备技术开发与示范
CN114010665A (zh) * 2021-11-30 2022-02-08 西南医科大学附属医院 罗伊氏乳杆菌在制备预防和/或治疗酒精性肝病的药物中的应用
CN115494244B (zh) * 2022-11-21 2023-03-24 保定佳瑞源生物芯片有限公司 一种癌抗原ca724的吖啶酯抗体标记稀释液及其应用
CN117187145B (zh) * 2023-10-20 2024-07-16 深圳保时健生物工程有限公司 一株具有降脂、降血糖和减重功能的嗜酸乳杆菌goldgut-la100及其应用
CN118497081B (zh) * 2024-07-09 2024-10-11 云南大学 一种发酵粘液乳杆菌iobra9848及其分离方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
NL9101537A (nl) 1991-09-11 1993-04-01 Tno Lactobacilli met genetisch gemodificeerde galzouthydrolytische activiteit, produktie en toepassing daarvan.
US5716615A (en) * 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
US5686276A (en) * 1995-05-12 1997-11-11 E. I. Du Pont De Nemours And Company Bioconversion of a fermentable carbon source to 1,3-propanediol by a single microorganism
US5534253A (en) * 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
GB9601333D0 (en) 1996-01-23 1996-03-27 Univ Mcgill Microencapsulated genetically engineered microorganisms for clinical application
KR100387245B1 (ko) 1997-10-17 2003-08-19 일양약품주식회사 유산균의안정화를위한미세장용성코팅과립
US6811786B1 (en) 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
DE19956400B4 (de) 1999-11-24 2005-09-08 Sagredos, Angelos, Prof. Dr. Therapeutisch wirksame Zusammensetzung, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
EP1264893A1 (en) 2001-06-08 2002-12-11 Teagasc Dairy Products Research Centre CLA biosynthesis by bifidobacteria
EP2591771A1 (en) * 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
CA2517245C (en) 2003-02-28 2009-01-20 Mcgill University Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
AU2005294200A1 (en) * 2004-10-08 2006-04-20 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
EP2046352A4 (en) 2006-06-06 2012-03-21 Univ Mcgill FERMENTED MILK PRODUCT AND ITS USE
EP2061483A1 (en) * 2006-09-07 2009-05-27 McGill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
CN101273757B (zh) * 2008-03-31 2011-02-09 北京市农林科学院 罗伊氏乳酸杆菌冻干制剂及其制备方法
RU2571211C2 (ru) * 2009-05-01 2015-12-20 ЮАС ЛЭБОРЭТОРИЗ ЭлЭлСи Бактериальные композиции для профилактики и лечения дегенеративного заболевания

Also Published As

Publication number Publication date
RU2011148944A (ru) 2013-06-10
DK2419114T3 (en) 2016-07-25
AU2010242498A1 (en) 2011-12-22
ES2578081T5 (es) 2019-10-16
KR20120015335A (ko) 2012-02-21
US10660857B2 (en) 2020-05-26
EP3067056A1 (en) 2016-09-14
HRP20160598T1 (hr) 2016-07-29
PL2419114T5 (pl) 2019-09-30
EP2419114B1 (en) 2016-04-20
WO2010124387A1 (en) 2010-11-04
RU2571211C2 (ru) 2015-12-20
BRPI1009920A2 (pt) 2016-03-15
US20110217368A1 (en) 2011-09-08
JP2012525338A (ja) 2012-10-22
ES2578081T3 (es) 2016-07-20
EP2419114A4 (en) 2013-07-31
CA2796929C (en) 2020-03-10
JP6100526B2 (ja) 2017-03-22
HRP20160598T4 (hr) 2019-06-28
CN102481322A (zh) 2012-05-30
EP2419114B2 (en) 2019-02-27
JP2015127338A (ja) 2015-07-09
EP2419114A1 (en) 2012-02-22
DK2419114T4 (da) 2019-05-27
CA2796929A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
HRP20160598T1 (hr) Bakterijski sastavi za prevenciju i liječenje degenerativne bolesti
IL220613A0 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
EP2473054A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
EP2440220A4 (en) COMPOSITIONS AND METHOD FOR PREPARING COMPOSITIONS FOR PREVENTING AND TREATING HYPERTENSION
EP2141989A4 (en) COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS
HRP20141057T1 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
EP2182810A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING OSTEOARTHRITIS
PL2445510T3 (pl) Kompozycja do leczenia zwyrodnieniowych chorób stawów
EP2459206A4 (en) METHODS OF TREATMENT USING THYMUS-BASED COMPOSITIONS
IL214979A0 (en) Compositions and methods for elimination of gram-negative bacteria
HK1165320A1 (en) Composition for treatment and/or prevention of dermatopathy
HK1167101A1 (en) Compositions and methods for treatment of multiple sclerosis
PT2403336E (pt) Composições de tratamento de plantas e métodos para a sua utilização
GB0902040D0 (en) Composition for treatment of skin
IL218448A0 (en) Compositions for treatment of neuropathic pain
EP2417258A4 (en) BACTERIOPHAGE COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS
HUP0900364A2 (en) Preventive composition for treatment of disease of honey-bees caused by ccd
HK1170958A1 (en) Compositions for treatment and prevention of diabetic complications using osteomeles schwerinae
IL216453A0 (en) Natural compositions for the treatment of lice
AU2009900091A0 (en) Methods of treatment and prophylaxis
GB0911418D0 (en) Treatment of degenerative disc disease